OMIDRIA changes the approach to intraoperative miosis and postoperative ocular pain1-4
OMIDRIA Mechanism of Action
The two active pharmaceutical ingredients in OMIDRIA, phenylephrine and ketorolac, act to maintain pupil size by preventing intraoperative miosis. Postoperative pain is also reduced.
Ketorolac is a non-steroidal anti-inflammatory that inhibits both COX-1 and COX-2, resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma.
By inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, ketorolac also prevents surgically induced miosis.
Phenylephrine is an α1-adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris.
REFERENCES: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. 2. Donnenfeld ED, Shojaei RD. Effect of intracameral phenylephrine and ketorolac 1.0%/0.3% on intraoperative pain and opioid use during cataract surgery. Clin Ophthalmol. 2019;13:2143-2150. 3. Schechter BA. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clin Ophthalmol. 2019;13:1439-1460. 4. Zhu L, Zhang Y, Guo Z, Wang M. Cardiovascular biology of prostanoids and drug discovery. Arterioscler Thromb Vasc Biol. 2020;40(6):1454-1463.